Advanced Life Sciences Holdings, Inc. (ADLS) SEC Filing 10-Q Quarterly report for the period ending Wednesday, September 30, 2009

Exhibit 99.1

Advanced Life Sciences Announces Third Quarter 2009 Financial Results

CHICAGO, IL, November 10, 2009/PRNewswire/: —

The net loss allocable to common shareholders for the three months ended September 30, 2009 was $2.9 million or ($0.05) per share compared to a net loss allocable to common shareholders of $13.1 million or ($0.34) per share for the three months ended September 30, 2008.  The decrease in the net loss is due to a $10.0 million milestone expense incurred under the license agreement with Abbott in the third quarter of last year as well as decreased costs related to regulatory expenses and development activities involving the Company’s lead compound, Restanza™ (cethromycin).

The Company ended the third quarter of 2009 with cash and cash equivalents totaling $4.2 million.  Cash used for operations during the quarter was approximately $4.5 million.

“In the third quarter, we continued to advance Restanza on two significant fronts: in community acquired pneumonia (CAP) and as a broad spectrum countermeasure for biodefense,” said Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences. “In CAP, we are in ongoing discussions with the FDA to identify the scope and protocol design for the additional clinical data that would be required to satisfy the FDA’s request for additional efficacy information to complete the clinical development program. In biodefense, we made exciting progress by generating positive pivotal data in anthrax and plague and receiving orphan designation in tularemia and plague.”

Dr. Flavin added: “As another indication of the government’s interest in Restanza as a biodefense agent, the Company was invited to submit a full proposal in response to a Broad Agency Announcement (BAA) issued by the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services for the advanced development of Restanza as a broad spectrum countermeasure for biodefense. BARDA funding could significantly help to advance Restanza toward approval by the FDA as an important medical countermeasure, and toward consideration by the government for acquisition and stockpiling.”

Operating Expense Analysis

·                  Research and development expenses were $0.9 million for the three months ended September 30, 2009 compared to $11.2 million for the three months ended September 30, 2008.  This difference was primarily due to the $10.0 million milestone expense incurred under our license agreement with Abbott in the third quarter of 2008.

·                  Selling, general and administrative expenses totaled $2.2 million for the three months ended September 30, 2009 compared to $1.8 million for the same period in 2008.

-MORE-